AI Science Tracker

Kyushu University

1 discovery from 2022

Discoveries

LIGHTHOUSE identifies riboflavin 5′-monophosphate as a PPAT inhibitor

LIGHTHOUSE, a deep-learning model using protein sequence and chemical representations, nominated riboflavin 5′-monophosphate as an inhibitor of PPAT, a target without reported inhibitors in the paper. A biochemical assay measured PPAT inhibition with an IC50 of 7.5 μM, close to the model’s predicted range; the same study also tested predicted antiviral compounds in cell models.

Technology: LIGHTHOUSE (ensemble graph-based deep-learning platform)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: LIGHTHOUSE, a deep-learning model using protein sequence and chemical representations, nominated riboflavin 5′-monophosphate as an inhibitor of PPAT, a target without reported inhibitors in the paper.
  • Still unknown: The result is an in-vitro enzyme assay, not a validated anticancer treatment. The authors note LIGHTHOUSE can produce false positives; COVID-19 results were also cell-based and had no clinical evidence.
  • AI role: The model scored protein–compound relationships without requiring a 3D target structure and prioritized the compound from >333,000 candidates for experimental follow-up. The authors assayed PPAT activity and confirmed inhibition in vitro.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9549714/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 57 of works of the same type, year and subfield (OpenAlex work metrics, 9 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.